drugset / Trial / NCT04838860
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase 2 study to investigate the safety, tolerability, and efficacy of administering increased siltuximab doses to patients with iMCD
Timeline
- Start
- 2021-03-31
- Primary completion
- 2021-04-01
- Completion
- 2021-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Siltuximab | Monoclonal antibody | 22 mg/kg | Intravenous |
| Comparator | Siltuximab | Monoclonal antibody | 33 mg/kg | Intravenous |
| Comparator | Siltuximab | Monoclonal antibody | 44 mg/kg | Intravenous |